Biogen today, announced plans to initiate a global Phase 3b clinical study, ASCEND. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of SPINRAZA™ in children, teens and adults with later-onset spinal muscular atrophy (SMA) following treatment with Evrysdi® (risdiplam).
Pioneers in Neuroscience
Biogen Canada Inc. is exceptionally proud to announce that it has been recognized as one of the “Top 50 Best Workplaces™” in Canada and has also been named one of the “Top 50 Best Workplaces™ for Women” in Canada.
Biogen Canada is proud to announce that it has been certified as a Great Place to Work® (GPTW) and named to the 2020 list of Best WorkplacesTM in Healthcare.
Time is of the essence when it comes to preserving motor neuron function in SMA. Early diagnosis and management of this debilitating neurodegenerative condition which is the leading cause of genetic death in infants is crucial. We are proud to have contributed to the newborn screening pilot study at CHEO to lay the groundwork for adding SMA to routine newborn screening panels.
SMA Awareness Month is a time for the entire SMA community to come together and raise awareness to improve outcomes for patients across Canada.
Stepping up to support Canadian communities during the COVID-19 pandemic
The impact of the COVID-19 pandemic is being felt around the world and by so many. More than ever, our communities need us and are counting on our support. This is the rationale behind the Biogen Foundation $10M global commitment to address the immediate needs of communities and hospital systems.
TO PATIENTS, HEALTHCARE PROVIDERS, PARTNERS, AND OUR COMMUNITY
As the novel coronavirus (COVID-19) outbreak evolves in Canada and around the world, the health and safety of all those who are impacted in any way is our utmost concern.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
The Biogen Canada team proudly shared with Canadians important results from the NURTURE clinical trial published in Neuromuscular Disorders. A press release issued on the Canadian newswire included reaction from the SMA community underscoring the critical need for newborn screening for SMA across the country.
There is also good news for patient access to SPINRAZA™ in Canada in Maritime province of Nova Scotia which has now joined several other provinces to have expanded access. The Canadian team is committed to ensuring SMA patients across Canada have equal access to the best possible care and will continue their work to ensure the remaining provinces: British Columbia, Manitoba, Prince Edward Island and Newfoundland & Labrador will soon follow suit.
The Ontario government expands coverage for SPINRAZA™.
Saskatchewan has become the second province in Canada to grant broad access to SPINRAZA™ for SMA patients.
This is an important milestone for the SMA community and allows more patients in Alberta who have been diagnosed with this rare condition to be eligible for reimbursement.
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.